However, despite some cases showing exceptional responses [10, 11], the majority of IGF/IGF‐1R inhibitor trials failed due to factors including lack of predictive biomarkers, dose‐limiting hyperglycaemia resulting from INSR co‐inhibition, and incomplete understanding of IGF‐1R biology [12]. This evidence concerns the gene IGF1R and Hyperglycemia.